Daily Weight Loss Pill Moves Closer to European Approval

2026-10-19 companies

Amsterdam, Monday, 19 October 2026.
European regulators recommended Eli Lilly’s daily pill Foundayo for weight management and diabetes. Unlike competitors, patients can take this flexible oral treatment anytime without food or water restrictions.

Regulatory Milestone and Market Context

Eli Lilly (NYSE: LLY) has achieved a significant regulatory advancement as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Foundayo on 15 October 2026 [2][3]. This recommendation supports the granting of marketing authorization for the oral treatment of type 2 diabetes mellitus and weight management in adults, moving the pharmaceutical leader closer to formal European Commission approval [2]. This development follows previous momentum that saw Eli Lilly surpass a $1.1 trillion market value, driven by strong demand for its weight-loss therapies [GPT]. The final decision now rests with the European Commission, with approval expected within a few weeks of the CHMP recommendation [3][6].

The global obesity-treatment market is projected to exceed $100 billion by 2030, intensifying competition between Eli Lilly and Novo Nordisk [1]. Foundayo becomes the second weight-loss pill to receive a positive recommendation from the EMA, following the oral version of Wegovy which was approved in the European Union in July 2026 [1][6]. Eli Lilly has filed approval applications in over 40 countries and plans to work with health authorities to facilitate access, viewing obesity and type 2 diabetes as significant long-term commercial opportunities outside the United States [1][3].

Clinical Efficacy and Trial Results

The CHMP recommendation for weight management is supported by robust clinical data involving more than 4,740 adults across two studies [3][7]. In these trials, participants treated with Foundayo achieved weight loss of 5% to 11% after 72 weeks, compared to 2% to 2.5% for placebo groups [4][7]. The medication is indicated for adults with an initial Body Mass Index (BMI) of ≥ 30 kg/m² or ≥ 27 kg/m² with weight-related comorbidities such as hypertension or cardiovascular disease [2][7].

For type 2 diabetes, the evaluation involved four main studies comprising 3,765 adults whose glucose levels were inadequately controlled [4]. Foundayo reduced HbA1c levels by 1.2 to 1.9 percentage points, outperforming placebo reductions of 0.4 to 0.8 percentage points [4][8]. The most common side effects reported during dose escalation include gastrointestinal issues such as nausea, vomiting, and diarrhea, though these decreased in frequency over time [2][4].

Administration and Competitive Advantages

Foundayo is based on orforglipron, a non-peptide small molecule GLP-1 receptor agonist designed for daily oral administration [3][6]. A key differentiator is its administration flexibility; the pill can be taken at any time of day without food-related requirements or restrictions on water intake [1][6]. This contrasts with competitors like oral semaglutide products, which require an overnight fast and a 30-minute wait before consuming anything [6][8].

Commercially, Foundayo generated $98 million in sales in Q2 2026, compared with approximately $484.5 million for the Wegovy pill during the same period [1]. The sales gap stands at 386.5 million, highlighting the market share held by the earlier entrant [1]. Despite slower initial adoption compared to Wegovy, Eli Lilly is counting on the convenience of the pill to improve treatment adherence in an increasingly competitive environment [1][6].

Global Expansion and Future Outlook

Eli Lilly intends to utilize international regulatory approvals for orforglipron as a primary driver for near-term financial performance [3]. While the rollout for diabetes will depend on national reimbursement policies, the obesity indication could launch in Europe by the end of the year [1]. The company’s injectable incretin therapies previously accounted for 65% of total revenue during the first half of 2026, indicating the strategic importance of diversifying into oral formats [3].

As the European Commission reviews the CHMP recommendation, subsequent price and reimbursement decisions will be determined by individual Member States [4]. This regulatory step solidifies Eli Lilly’s position in the oral GLP-1 market, providing a noninjectable incretin-based treatment option alongside its existing portfolio [7][8].

Sources

Eli Lilly Obesity Treatment